Polypeptide Group Definitive Interim Result Of The Public Tender Offer Of Samsung Biologics

By Reuters News

- POLYPEPTIDE GROUP AG PPGN.S:

  • DEFINITIVE INTERIM RESULT OF THE PUBLIC TENDER OFFER OF SAMSUNG BIOLOGICS CO., LTD.

  • SAMSUNG PEPTIDE HOLDS 87.92% OF POLYPEPTIDE SHARE CAPITAL

  • 87.59% OF POLYPEPTIDE SHARES TENDERED INTO OFFER

  • MINIMUM ACCEPTANCE RATE CONDITION OF OFFER SATISFIED

  • NO MATERIAL ADVERSE EFFECT CONDITION OF OFFER SATISFIED

  • SAMSUNG PEPTIDE DECLARES OFFER SUCCESSFUL SUBJECT TO REMAINING CONDITIONS

  • DEAL COMPLETION EXPECTED END OF 2026 OR Q1 2027

  • TO HOLD EXTRAORDINARY GENERAL MEETING ON OCT 26, 2026

  • SAMSUNG PEPTIDE TO PURSUE SQUEEZE-OUT AND DELISTING OF POLYPEPTIDE SHARES

  • ADDITIONAL ACCEPTANCE PERIOD FOR OFFER FROM OCT 19 TO OCT 30, 2026

Further company coverage: PPGN.S

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk